The global integrin alpha V market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Integrins are proteins that function mechanically. They attach to the cell cytoskeleton to the extracellular matrix (ECM), and biochemically through sensing if adhesion has occurred. The integrin family consists of two types of protein including alpha and beta subtypes. Integrin alpha-V is a protein that is encoded by the ITGAV gene in humans. The major factor driving the demand for the global integrin alpha V market is the rising prevalence of the respiratory disease across the globe. 

According to the World Health Organization (WHO), Some common chronic respiratory disease includes asthma, occupational lung diseases and pulmonary hypertension. Additionally, as per the same source, asthma is common among children and an estimated 235 million people suffer from it. Furthermore, more than 90% of mortalities from respiratory disease occurs in low income and middle-income countries. Moreover, there is a mortality rate of more than 3 million people with an estimated 6% of all deaths globally. Additionally, integrin alpha V supports in selective retention of lymphocytes in mucosal tissues of the lung. Hence, the rising prevalence of respiratory disease is driving the demand for integrin alpha V, which in turn, is driving the growth of the market.

Some major players operating in the market include Biogen Inc., Merck KGaA, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2021, Corbus Pharmaceuticals announced that it is expanding its pipeline in immuno-oncology and fibrotic disease by launching two monoclonal antibodies (mAbs) including CRB-601 and CRB-602. CRB-601 is a high potency anti-alpha V beta 8 (anti-avb8 mAb) antibody, while CRB-602 antibody inhibits both alpha V beta 6 and alpha V beta 8.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Biogen Inc., Merck KGaA, and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Integrin Alpha V Market Report by Segment

By Type 

• MK-0429
• C-16Y
• 264-RAD
• AC-301
• Others

By Application 

• Metabolic Disorders
• Ophthalmology
• Respiratory
• Infectious Disease
• Others

Global Integrin Alpha V Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa